The Emmes Corporation announced that it was selected as one of the best places to work in the greater Washington area. The Washington Post’s 2018 Top Workplaces list ranked private, public, nonprofit and government agencies based on the highest engagement ratings from their employees. The Washington Post partnered with employee research and consulting firm Energage, formerly Workplace Dynamics, to conduct the survey, with more than 2,800 area companies invited to participate.
The Top Area Workplace awards, which are based solely on employee survey feedback, honored 150 organizations as Top Workplaces. Emmes was ranked 20th out of 25 in the large company category and was one of only two biotechnology organizations to make the list.
“We are proud to be honored for a third consecutive year,” said Dr. Anne Lindblad, president and chief executive officer of Emmes. “At the conclusion of the Top Workplaces survey, we learned that one of our employees had written: 'I am one small part of a very impressive research community that is making incredible advances in healthcare.'
The Emmes Corporation today announced that scientists and health professionals from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have completed a multi-year clinical trial testing hyperbaric oxygen as an intervention for U.S. military service members who have suffered mild traumatic brain injuries with persistent symptoms.
The Emmes Corporation today announced the creation of an internship program in which the company will offer one fellow from Egypt’s Children Cancer Hospital an internship to gain training and experience in clinical research. Under the new program, one fellow will be selected each year to travel to Emmes’ headquarters in Rockville, Maryland, to work with its clinical research experts. The duration of each internship will be determined on a case-by-case basis.
The Emmes Corporation today announced the completion of a pivotal clinical trial for a new product developed by IDx that could help in detecting diabetic retinopathy, the leading cause of blindness in the United States. IDx-DR is a fully autonomous AI-based diagnostic system that analyzes images of the retina for signs of diabetic retinopathy, providing instructions for follow-up care based on the level of disease detected. IDx-DR has been granted expedited review by the Food and Drug Administration.
The Emmes Corporation today announced its participation in a three-year study testing the results of two different opioid treatment medications. The research, published in one of the world’s oldest and best known medical journals, concluded that for those able to begin treatment, both drugs are nearly equal in their safety and effectiveness. The National Institute on Drug Abuse (NIDA) funded the research.
In addition to providing data management and statistical support, Emmes served as the clinical coordinating center. This involved protocol development, pharmacovigilance, quality assurance, safety monitoring and regulatory support. The clinical trial occurred between 2014 to 2017 at eight community treatment programs across the U.S. A total of 570 patients participated, with each group followed for a 24-week period.